Skip to content
香港聯合腫瘤中心
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En

Category: 乳癌

Phase 3 randomized, double-blind study in first-line ER+ (≥1%), HER2− advanced/metastatic breast cancer comparing palazestrant + ribociclib vs letrozole + ribociclib. Includes key inclusion/exclusion criteria and dosing details. Contact Hong Kong United Oncology Centre.

NCT07085767: OPERA-02 Study

The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with estrogen receptor-positive (ER+), HER2-negative (HER2−) advanced/metastatic breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the eligibility criteria for this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.

立即閱讀
December 18, 2025 No Comments
李宇聰醫生主講「擁抱希望 - 早期乳癌新認知」講座 | 全球華人乳癌組織聯盟 GCBC × 香港聯合腫瘤中心 HKUOC | 2025年10月31日

Dr. Li Yu Chung, Jacky will present a lecture titled "Embracing Hope – New Understanding of Early Breast Cancer" | Global Chinese Breast Cancer Organization Alliance (GCBC) × HKUOC | October 31, 2025

2025年10月31日（星期五），香港聯合腫瘤中心（HKUOC）臨床腫瘤科李宇聰醫生應邀在全球華人乳癌組織聯盟（GCBC）的患者教育講座中，分享早期乳

立即閱讀
December 2, 2025 No Comments
2025年9月18日 宏利健康講座：肺癌、乳癌及前列腺癌治療新趨勢 - 香港聯合腫瘤中心李宇聰醫生分享

Manulife Health Seminar, September 18, 2025: New Trends in the Treatment of Lung Cancer, Breast Cancer, and Prostate Cancer – Dr. Li Yu-chung of the Hong Kong United Oncology Centre shares his insights.

On September 18, 2025, Dr. Li Yu Chung, Jacky of the Department of Clinical Oncology at the Hong Kong United Oncology Centre (HKUOC) will share the latest treatment trends in lung cancer, breast cancer, and prostate cancer at the Manulife Health Seminar. The seminar will be held at Manulife Tower in Kwun Tong from 10:30 a.m. to 11:30 a.m. All are welcome to attend and learn about the cutting-edge treatment technologies and personalized plans!

立即閱讀
December 1, 2025 No Comments

NCT06966700: Trofuse-032/MK2870-032 Research

Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with high-risk early-stage triple-negative breast cancer (TNBC) or hormone receptor-weak positive/HER2-negative breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the criteria for participation in this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.

立即閱讀
November 19, 2025 No Comments
2025年肺癌治療新趨勢 - 李宇聰醫生於AIA講座分享

New trends in the treatment of lung cancer, breast cancer, and prostate cancer｜Patient Guide (Excerpted from AIA Internal Sharing｜2025/07/30)

2025年7月30日，香港聯合腫瘤中心（HKUOC）李宇聰醫生於AIA健康教育分享會講解肺癌、乳癌、前列腺癌治療新趨勢。包括標靶治療、免疫治療、ADC、SBRT及177Lu-PSMA等最新技術，僅供教育參考，助患者了解就醫重點與個人化治療方案。

立即閱讀
August 12, 2025 No Comments

Oral SERD drugs will change the pattern of hormone receptor-positive breast cancer treatment

口服SERD藥物將改變荷爾蒙受體陽性乳腺癌治療格局 雌激素受體抑制 雖是荷爾蒙受體陽性乳腺癌的有效治療手段，但傳統內分泌治療存在 藥代動力學限制 和

立即閱讀
July 4, 2025 No Comments

【240711 Team Medicine Sharing Seminar】 New Trends in the treatment of lung cancer, breast cancer and prostate cancer

With advancements in medicine, cancer treatment has entered an era of precision and personalized care. Taking lung cancer, Hong Kong's leading cancer killer, as an example, next-generation sequencing technology can detect over 300 cancer genes at once, helping doctors screen and find the most appropriate treatment plan or clinical trial program. This not only avoids delaying treatment but also makes better use of limited resources to maximize benefits for patients.

立即閱讀
November 11, 2024 No Comments
晚期癌症患者的新治療選擇_建議及早安排HER2 蛋白表達的 IHC 免疫組織化學 測試

A new treatment option for patients with advanced cancer! It is recommended to arrange an IHC immunohistochemical test for HER2 protein expression as soon as possible

  在2024年4月5日，FDA對fam-trastuzumab deruxtecan-nxki（品牌名稱Enhertu）授予加速批准，適用

立即閱讀
October 23, 2024 No Comments
癌症資訊影片

Hong Kong United Oncology Centre (Hong Kong United Oncology Centre) Introduction

立即閱讀
October 14, 2024 No Comments
香港聯合腫瘤中心 - 專業肺癌治療與臨床研究服務

BAY 2927088

Clinical studies recruiting patients with advanced non-small cell lung cancer (NSCLC) with EGFR and/or HER2 mutations

立即閱讀
September 27, 2024 No Comments
Page1 Page2 Page3 Page4 Page5
香港聯合腫瘤中心

The Hong Kong United Oncology Centre (HKUOC) provides cancer-related medical services such as cancer screening, cancer diagnosis and cancer treatment, including immunotherapy, chemotherapy, targeted drug therapy, radiation therapy, hormone therapy and palliative care.

Contact us

  • Address: Rooms 01-06, 20/F, 238 Nathan Road, Kowloon (MTR Jordan Station Exit E)
  • Phone: +852 2386 8002
  • WhatsApp：5518 2992
  • Fax: (852) 2386 8229
  • Macau: Enquiry@hkuoc.hk

Consultation time

Monday to Friday

9:00 am to 1:00 pm

2:00 p.m. to 6:00 p.m.

Saturday

9:00 am to 1:00 pm

Closed on Sundays and public holidays

Types of cancer

  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer
  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer

Cancer treatment

  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy
  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy

phone

WhatsApp

Facebook